
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical is projected to experience substantial growth with EBITDA increasing from $24.6 million in FY26 at a margin of 16.8% to $27.3 million in FY27 at a margin of 19.1%. Additionally, the company's free cash flow is expected to rise from $5.1 million in FY26 to $6.0 million in FY27, reflecting improved financial health. These metrics indicate a positive trajectory for operational efficiency and profitability within the contract development and manufacturing space.
Bears say
Lifecore Biomedical's stock outlook is negatively impacted by a projected revenue growth rate that is expected to lag behind market averages, particularly in the fill/finish segment influenced by small molecule injectables. The company's high leverage ratio further complicates its financial position, suggesting increased risk when compared to peers. Additionally, the anticipated lack of meaningful revenue growth until calendar year 2027 raises concerns about the company's ability to generate profits in the near term.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares